Guardant Health (GH) 44th Annual J.P. Morgan Healthcare Conference summary

Strategic vision, mission, and platform innovation

• Mission centers on extending disease-free life and advancing human health through pioneering liquid biopsy, integrated blood-based cancer testing, and earlier disease detection.

• Smart platform leverages proprietary chemistry, advanced algorithms, and Infinity AI to drive multimodal biology, product innovation, and clinical insights.

• Over 1 million patients tested, with products ordered by 12,000+ oncologists and thousands of primary care physicians.

• Infinity AI enables rapid development of smart apps, clinical navigation, and commercial intelligence tools.

• Platform supports therapy selection, MRD, early cancer detection, and is expanding into multi-disease screening and other disease areas.

Financial performance and growth drivers

• Achieved $981 million in 2025 revenue, up 33% year-over-year, with Q4 revenue of $280 million (39% growth).

• Revenue has grown from $374 million in 2021 to $981 million in 2025.

• Oncology volumes grew 34% in 2025, with Guardant360 showing 25% year-over-year growth.

• Shield screening volumes rose sharply, with 38,000 tests in Q4 and strong adherence rates of 93%.

• Ended 2025 with $1.3 billion in cash, targeting free cash flow breakeven by Q4 2027, and generated positive free cash flow in Q3 and Q4 2025 excluding screening.

Product portfolio, clinical advancements, and innovation

• Guardant360 Liquid leads advanced cancer therapy selection, with new smart apps, RNA analysis, and Guardant360 Tissue boosting adoption.

• Reveal MRD test expanded into therapy monitoring, with Reveal Ultra launching for ultra-sensitive detection in 2026.

• Shield is the first FDA-approved blood test for CRC screening, now expanded to multi-cancer detection for nine cancers.

• Clinical evidence includes 1,200+ conference publications, 670+ peer-reviewed articles, and partnerships with 45+ NCI-designated cancer centers.

• Strategic collaborations with Quest Diagnostics and PathGroup broaden Shield’s reach nationally, expanding access to over 8,000 patient points and 650,000 EMR-connected providers.